Flexible Work, Better Balance
Eloxx Pharmaceuticals is at a critical stage of growth and patient impact. Backed by leading healthcare investors, we are advancing two Phase 2 studies in Alport Syndrome and ADPKD patients with nonsense mutations. These are rare diseases where every patient counts, and success could lead to the first approved therapies.
The Alport program is fully designed, IND cleared in the US, and pending MHRA and Ethics approvals in the UK. This study is expected to launch shortly and could provide a foundation for registration. The ADPKD program is in planning, creating a rare opportunity to build the program from the ground up.
This is a chance to get in on the ground floor of a company with momentum, take ownership of programs that truly matter, and advance therapies for patients with no treatment options.